Erik E. Chiong Espinoza

Erik E. Chiong Espinoza

Auto-generated profile, based on publicly available information

Erik E. Chiong Espinoza

Medical Student, Universidad Peruana de Ciencias Aplicadas (UPC) Lima Peru

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2026 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
OBOrly Lender Barmac
Orly Lender Barmac
LTLucero Riva Torre
Lucero Riva Torre
THTahmina Haque
Tahmina Haque
EEErik E. Chiong Espinoza
Erik E. Chiong Espinoza
PCPaolo S. Chavez Cavalie
Paolo S. Chavez Cavalie

28 October 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PMPedro Giavarini Mansk
Pedro Giavarini Mansk
VKVanisha Kumar
Vanisha Kumar
AFAna Maria T. Fagundes
Ana Maria T. Fagundes
EEErik E. Chiong Espinoza
Erik E. Chiong Espinoza
RMRomán Rodríguez Milán
Román Rodríguez Milán
KMKunal Mahajan
Kunal Mahajan

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
RMRoman Rodriguez Milan
Roman Rodriguez Milan
NNNyree Nava Nogueda
Nyree Nava Nogueda
MAMuhammad Sharjeel Abbas
Muhammad Sharjeel Abbas
AAAshfaq Ahmad
Ashfaq Ahmad
EEErik E. Chiong Espinoza
Erik E. Chiong Espinoza
FFFlavia Castro Velasco Fernandes
Flavia Castro Velasco Fernandes
Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder in which eosinophilic inflammation represents a treatable trait associated with increased exacerbation risk. Randomized trials (RCTs) of mepolizumab in eosinophilic COPD have shown variable results, and the magnitude of clinical benefit remains uncertain.MethodsWe performed a systematic review and meta-analysis of RCTs evaluating mepolizumab in eosinophilic COPD. Frequentist random-effects models were used to estimate pooled effects, and complementary Bayesian analyses were conducted to quantify the probability of treatment benefit.ResultsFour RCTs comprising 1,953 patients of whom 978 (50.1%) underwent mepolizumab were analyzed. Mepolizumab significantly reduced the annual rate of moderate or severe exacerbations (IRR 0.80; 95% CI: 0.75 to 0.86) and prolonged the time to first exacerbation (HR 0.78: 95% CI: 0.69 to 0.88). Bayesian analyses showed a posterior probability of high benefit for exacerbation-related outcomes. Similarly, a reduction in exacerbations requiring emergency care was observed (IRR 0.77; 95% CI: 0.60 to 1.00) with no increased risk for adverse events, treatment discontinuation, or mortality. Conclusion In eosinophilic COPD, mepolizumab reduces exacerbation frequency and delays time to first exacerbation without compromising safety. These findings support targeting IL-5-mediated eosinophilic inflammation in selected COPD populations.